HR 6710
117th Congress
House
Health
Congressional oversight
Drug safety, medical device, and laboratory regulation
Emergency medical services and trauma care
Infectious and parasitic diseases
Manufacturing
Trade restrictions
To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to submit to Congress a report on barriers, including regulatory inefficiencies, to domestic manufacturing of active pharmaceutical ingredients, finished drug products, and devices, and for other purposes.
Introduced: February 11, 2022
See on congress.gov
Everywhere this bill has been
3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Feb 14, 2022
Referred to the Subcommittee on Health.
Feb 11, 2022
Referred to the House Committee on Energy and Commerce.
Feb 11, 2022
Introduced in House
Plain-English summary
This bill requires the Food and Drug Administration (FDA) to report to Congress on barriers to the domestic manufacturing of imported active pharmaceutical ingredients, finished drug products, and devices that are critical to public health.
The report must recommend strategies to overcome such barriers. The FDA may, to the extent appropriate, implement the strategies.
What's happening now
Referred to the Subcommittee on Health.
Committees of jurisdiction
2